Circulating long RNAs in serum extracellular vesicles: Their characterization and potential application as biomarkers for diagnosis of colorectal cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 7, 2016, Pages 1158-1166

  Dong, Lei ^a,b   Lin, Wanrun ^a,b   Qi, Peng ^a,b   Xu, Mi Die ^a,b   Wu, Xiaoben ^c   Ni, Shujuan ^a,b   Huang, Dan ^a,b   Weng, Wei Wei ^a,b   Tan, Cong ^a,b   Sheng, Weiqi ^a,b   Zhou, Xiaoyan ^a,b   Du, Xiang ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LONG UNTRANSLATED RNA; MESSENGER RNA; RNA; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; APOPTOTIC BODY; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CELL BODY; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EXOSOME; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEMBRANE MICROPARTICLE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SERUM; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; COLORECTAL TUMOR; GENETICS; METABOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COHORT STUDIES; COLORECTAL NEOPLASMS; EXOSOMES; EXTRACELLULAR VESICLES; FEMALE; HUMANS; MALE; MIDDLE AGED; RNA, LONG NONCODING; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 84977103339     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0006     Document Type: Article

References (34)

1. Are C, RajaramS, Are M, RajH, Anderson BO, Chaluvarya Swamy R, et al. A review of global cancer burden: Trends, challenges, strategies, and a role for surgeons. J Surg Oncol 2013;107:221-6
2. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104-17
3. Jass JR. Colorectal cancer: A multipathway disease. Crit Rev Oncog 2006;12:273-87
4. Orang AV, Barzegari A. MicroRNAs in colorectal cancer: From diagnosis to targeted therapy. Asian Pac J Cancer Prev 2014;15:6989-99
5. Xu MD, Qi P, Du X. Long non-coding RNAs in colorectal cancer: Implications for pathogenesis and clinical application. Mod Pathol 2014;27: 1310-20
6. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426-37
7. Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and RNA markers in blood: A tool for early detection, diagnostics, and followup? Lung Cancer 2005;49:1-12
8. Lo YM. Circulating nucleic acids in plasma and serum: An overview. AnnN Y Acad Sci 2001;945:1-7
9. Kopreski MS, Benko FA, Gocke CD. Circulating RNA as a tumor marker: Detection of 5T4 mRNA in breast and lung cancer patient serum. Ann N Y Acad Sci 2001;945:172-8
10. Dong L, Qi P, Xu MD, Ni SJ, Huang D, Xu QH, et al. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. Int J Cancer 2015;137:1128-35
11. El-Hefnawy T, Raja S, Kelly L, Bigbee WL, Kirkwood JM, Luketich JD, et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem 2004;50:564-73
12. Isin M, Ozgur E, Cetin G, Erten N, Aktan M, Gezer U, et al. Investigation of circulating lncRNAs in B-cell neoplasms. Clin ChimActa 2014;431:255-9
13. Lorenzen JM, Schauerte C, Kielstein JT, Hubner A, Martino F, Fiedler J, et al. Circulating long noncoding RNATapSaki is a predictor ofmortality in critically ill patients with acute kidney injury. Clin Chem 2015; 61:191-201
14. Ronnau CG, VerhaeghGW, Luna-Velez MV, Schalken JA. Noncoding RNAs as novel biomarkers in prostate cancer. BioMed Res Int 2014;2014:591703
15. Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem 2002;48:1647-53
16. Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 2010;10:297-308
17. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010;251:499-505
18. Ma R, Jiang T, Kang X. Circulating microRNAs in cancer: Origin, function and application. J Exp Clin Cancer Res 2012;31:38
19. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8
20. Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 2000;6:3823-6
21. Li Y, Elashoff D, Oh M, Sinha U, St John MA, Zhou X, et al. Serum circulating human mRNA profiling and its utility for oral cancer detection. J Clin Oncol 2006;24:1754-60
22. Zhou X, Yin C, Dang Y, Ye F, ZhangG. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep 2015;5:11516
23. Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived mini-RNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer 2013;49:2949-59
24. Xie H,MaH, Zhou D. PlasmaHULCas a promising novel biomarker for the detection of hepatocellular carcinoma. BioMed Res Int 2013;2013:136106
25. Revenfeld AL, Baek R, Nielsen MH, Stensballe A, Varming K, Jorgensen M. Diagnostic and prognostic potential of extracellular vesicles in peripheral blood. Clin Ther 2014;36:830-46
26. Svoboda M, Slyskova J, Schneiderova M, Makovicky P, Bielik L, Levy M, et al. HOTAIR long non-codingRNAis a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis 2014;35:1510-5
27. Hamilton SR, Nakamura S, Bosman FT, Quirke P, Boffetta P, Riboli E, et al. In: F. T. Bosman FC, R.H. Hruban, N.D. Theise, editors.WHOclassification of tumours of the digestive system. 4th ed. Lyon: IARC. p.134-46
28. Radonić A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun 2004;313:856-62
29. Efron B TR. Improvements on cross-validation: The 632 and thorn bootstrap method. J Am Stat Assoc 1997;92:548-60
30. Foucher Y. Construction of diagnostic or prognostic scoring system and internal validation of its discriminative capacities based on ROC curve and 0.632 and thorn boostrap resampling 2013 2013-12-27. Available from: https:// cran.r-project.org/web/packages/ROC632/index.html
31. Shantha Kumara HM, Grieco MJ, Caballero OL, Su T, Ahmed A, Ritter E, et al.MAGE-A3 is highly expressed in a subset of colorectal cancer patients. Cancer Immun 2012;12:16
32. Godinho M, Meijer D, Setyono-Han B, Dorssers LC, van Agthoven T. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells. J Cell Physiol 2011;226: 1741-9
33. Yahagi S, Shibuya K, Obayashi I, Masaki H, Kurata Y, Kudoh J, et al. Identification of two novel clusters of ultrahigh-sulfur keratin-associated protein genes on human chromosome. Biochem Biophys ResCommun 2004;318:655-64
34. Ostenfeld MS, Jeppesen DK, Laurberg JR, Boysen AT, Bramsen JB, Primdal-Bengtson B, et al. Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. Cancer Res 2014;74:5758-71